In summary, the current study has demonstrated that suppression of TRPM2 followed by inhibition of Ca2+ influx and induction of ROS and DNA damage is a critical event in mediating the induction of apoptosis and the therapeutic efficacy of osimertinib against EGFRm NSCLC. This evidence concerns the gene TRPM2 and non-small cell lung carcinoma.